journal article·2018-11-05Open access

Combined immunization against TGF-β1 enhances HPV16 E7-specific vaccine-elicited antitumour immunity in mice with grafted TC-1 tumours

Xiaojie Chu, Yang Li, Weiwei Huang, Xuejun Feng, Pengyan Sun, Yufeng Yao, Xu Yang, Wenjia Sun, Hongmei Bai, Cunbao Liu, Yanbing Ma

Abstract

Therapeutic vaccine appears to be a potential approach for the treatment of human papillomavirus (HPV)-associated tumours, but its efficacy can be dampened by immunosuppressive factors such as transforming growth factor (TGF)-β1. We sought to investigate whether active immunity against TGF-β1 enhances the anti-tumour immunity elicited by an HPV16 E7-specific vaccine that we developed previously. In this study, virus-like particles of hepatitis B virus core antigen were used as vaccine carriers to deliver either TGF-β1 B cell epitopes or E7 cytotoxic T-lymphocyte epitope. The combination of preventive immunization against TGF-β1 and therapeutic immunization with the E7 vaccine significantly reduced the growth of grafted TC-1 tumours in C57 mice, showing better efficacy than immunization with only one of the vaccines. The improved efficacy of combined immunization is evidenced by elevated IFN-γ and decreased IL-4 and TGF-β1 levels in cultured splenocytes, increased E7-specific IFN-γ-expressing splenocytes, and increased numbers of CD4+IFN-γ+ and CD8+IFN-γ+ cells and decreased numbers of Treg (CD4+Foxp3+) cells in the spleen and tumours. The results strongly indicate that targeting TGF-β1 through active immunization might be a potent approach to enhancing antigen-specific therapeutic vaccine-induced anti-tumour immune efficacy and providing a combined strategy for effective cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Hepatitis B Virus Studies · Immune Response and Inflammation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China;

Yunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Disease, Kunming, China;

Yunnan Engineering Research Center of Vaccine Research and Development on Severe Infectious Disease, Kunming, China

Funding

the CAMS Initiative for Innovative Medicine · the Science and Technology Project of Yunnan Province · the National Natural Science Foundation of China · Fundamental Research Funds for Institute of Pathogen Biology of PUMC · the Peking Union Medical College (PUMC) Youth Fund and the Fundamental Research Funds for the Central Universities of China

References (47)

Show source-provided references
1. 10.2147/TCRM.S85610.2147/TCRM.S856 ↗
2. 10.2165/00063030-200822030-0000610.2165/00063030-200822030-00006 ↗
3. 10.1097/INF.000000000000077310.1097/INF.0000000000000773 ↗
4. 10.1517/14712598.8.4.42110.1517/14712598.8.4.421 ↗
5. 10.1586/erv.13.2310.1586/erv.13.23 ↗
6. 10.1016/j.ygyno.2007.05.03810.1016/j.ygyno.2007.05.038 ↗
7. 10.1016/j.ygyno.2007.04.03810.1016/j.ygyno.2007.04.038 ↗
8. 10.1097/01.AOG.0000110246.93627.1710.1097/01.AOG.0000110246.93627.17 ↗
9. Klencke B · Clin Cancer Res · 2002 · 8 · 1028
10. 10.1067/mob.2003.25610.1067/mob.2003.256 ↗
11. 10.1002/ijc.2302210.1002/ijc.23022 ↗
12. Davidson EJ · Cancer Res · 2003 · 63 · 6032
13. 10.1136/ijgc-00009577-200605000-0002010.1136/ijgc-00009577-200605000-00020 ↗
14. 10.3390/vaccines202042210.3390/vaccines2020422 ↗
15. 10.1080/21645515.2015.113603910.1080/21645515.2015.1136039 ↗
16. 10.1182/blood-2005-02-060710.1182/blood-2005-02-0607 ↗
17. 10.1016/j.canlet.2008.03.01210.1016/j.canlet.2008.03.012 ↗
18. 10.4049/jimmunol.166.1.67810.4049/jimmunol.166.1.678 ↗
19. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
20. 10.1172/JCI3142210.1172/JCI31422 ↗
21. 10.1080/21691401.2018.147052810.1080/21691401.2018.1470528 ↗
22. 10.1016/j.semcancer.2005.11.00510.1016/j.semcancer.2005.11.005 ↗
23. Nishikawa H · Int J Cancer · 2010 · 127 · 75910.1002/ijc.25429 ↗
24. 10.1038/srep1517910.1038/srep15179 ↗
25. 10.1016/j.cell.2008.05.00910.1016/j.cell.2008.05.009 ↗
26. 10.1038/ni153610.1038/ni1536 ↗
27. 10.1093/intimm/dxr12010.1093/intimm/dxr120 ↗
28. 10.1084/jem.192.2.30310.1084/jem.192.2.303 ↗
29. 10.1126/science.120294710.1126/science.1202947 ↗
30. 10.1038/ni118010.1038/ni1180 ↗
31. 10.3109/21691401.2015.101966910.3109/21691401.2015.1019669 ↗
32. 10.7314/APJCP.2015.16.16.681310.7314/APJCP.2015.16.16.6813 ↗
33. 10.1038/onc.2010.11210.1038/onc.2010.112 ↗
34. 10.1016/j.coph.2009.06.01410.1016/j.coph.2009.06.014 ↗
35. 10.1038/ni.374810.1038/ni.3748 ↗
36. 10.1146/annurev.immunol.16.1.13710.1146/annurev.immunol.16.1.137 ↗
37. 10.1158/1078-0432.CCR-07-165410.1158/1078-0432.CCR-07-1654 ↗
38. Shimizu J · J Immunol · 1999 · 163 · 521110.4049/jimmunol.163.10.5211 ↗
39. 10.1097/01.cji.0000178913.41256.0610.1097/01.cji.0000178913.41256.06 ↗
40. 10.1146/annurev.immunol.18.1.42310.1146/annurev.immunol.18.1.423 ↗
41. 10.1200/JCO.2005.04.571610.1200/JCO.2005.04.5716 ↗
42. Chu X · Int J Nanomedicine · 2016 · 11 · 2417
43. 10.1002/ibd.2116710.1002/ibd.21167 ↗
44. 10.4161/2162402X.2014.98976410.4161/2162402X.2014.989764 ↗
45. 10.1080/14760584.2016.117653310.1080/14760584.2016.1176533 ↗
46. 10.1016/j.ajog.2010.09.02010.1016/j.ajog.2010.09.020 ↗
47. 10.1126/scitranslmed.300732310.1126/scitranslmed.3007323 ↗